Evidence map›Paper›PMID 34344902›Full record

ArticleNPJ biofilms and microbiomes2021

A new BiofilmChip device for testing biofilm formation and antibiotic susceptibility.

Núria Blanco-Cabra, Maria José López-Martínez, Betsy Verónica Arévalo-Jaimes, María Teresa Martin-Gómez, Josep Samitier, Eduard Torrents

Abstract read
In one paragraph

Article in NPJ biofilms and microbiomes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. UnderstandingMicroorganisms · 2026
    Review
  8. Review
  9. Virulence · 2025
    Article
  10. Article
  11. Review
  12. Review
  13. Antibiofilm approaches as a new paradigm for treating infections.Progress in biomedical engineering (Bristol, England) · 2024
    Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Núria Blanco-Cabra *Bacterial Infections and Antimicrobial Therapies Group, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.ORCID 0000-0002-4784-1072
Maria José López-Martínez *Nanobioengineering Group, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
Betsy Verónica Arévalo-JaimesBacterial Infections and Antimicrobial Therapies Group, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.ORCID 0000-0002-3363-5403
María Teresa Martin-GómezMicrobiology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.ORCID 0000-0001-8119-8749
Josep SamitierNanobioengineering Group, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.
Eduard TorrentsBacterial Infections and Antimicrobial Therapies Group, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain. etorrents@ibecbarcelona.eu.ORCID 0000-0002-3010-1609

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently, three major circumstances threaten the management of bacterial infections: increasing antimicrobial resistance, expansion of chronic biofilm-associated infections, and lack of an appropriate approach to treat them. To date, the development of accelerated drug susceptibility testing of biofilms and of new antibiofouling systems has not been achieved despite the availability of different methodologies. There is a need for easy-to-use methods of testing the antibiotic susceptibility of bacteria that form biofilms and for screening new possible antibiofilm strategies. Herein, we present a microfluidic platform with an integrated interdigitated sensor (BiofilmChip). This new device allows an irreversible and homogeneous attachment of bacterial cells of clinical origin, even directly from clinical specimens, and the biofilms grown can be monitored by confocal microscopy or electrical impedance spectroscopy. The device proved to be suitable to study polymicrobial communities, as well as to measure the effect of antimicrobials on biofilms without introducing disturbances due to manipulation, thus better mimicking real-life clinical situations. Our results demonstrate that BiofilmChip is a straightforward tool for antimicrobial biofilm susceptibility testing that could be easily implemented in routine clinical laboratories.

Indexed as

Anti-Bacterial AgentsAnti-Infective AgentsBacterial InfectionsBacteriological TechniquesBiofilmsDelivery of Health CareHumansLaboratories, ClinicalMicrobial Sensitivity TestsMicrofluidicsMycobacterium tuberculosisPseudomonas aeruginosaStaphylococcus aureusAnti-Bacterial AgentsAnti-Infective Agents

Identifiers

PMID34344902
PMCPMC8333102

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.